Brief: Hemogenyx Pharmaceuticals Enters Feasibility Study Agreement With Nitto Denko
Mon 07:38
BRIEF-Hemogenyx Pharmaceuticals Enters Feasibility Study Agreement With Nitto Denko Oct 19 (Reuters) - Hemogenyx Pharmaceuticals PLC HEMO.L:
HEMOGENYX PHARMA PLC - FEASIBILITY STUDY AGREEMENT
HEMOGENYX PHARMACEUTICALS: ENTERS FEASIBILITY STUDY AGREEMENT WITH NITTO DENKO ON TARGETED LIPID NANOPARTICLE DELIVERY OF CAR MRNA
HEMOGENYX PHARMACEUTICALS: FEASIBILITY STUDY EXPECTED TO TAKE ABOUT FOUR MONTHS
Source text: ID:nRSS3937Za
Further company coverage: HEMO.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NITTO DENKO
See all newsBrief: Hemogenyx Pharmaceuticals Enters Feasibility Study Agreement With Nitto Denko
Brief: Nitto Denko Corporation - To Retire Treasury Shares Worth 2.28% Of Outstanding Stock On Oct 20
Table: Nitto Denko -Q1 group results (IFRS)
Table: Nitto Denko -2025/26 parent results
Table: Nitto Denko -2025/26 group results (IFRS)